Khwaja, Jahanzaib;
Keh, Ryan;
Smyth, Duncan;
Lunn, Michael Peter;
D'Sa, Shirley;
Sive, Jonathan;
(2022)
Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome.
EJHaem
, 3
(3)
pp. 1021-1024.
10.1002/jha2.492.
Preview |
Text
Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome.pdf - Published Version Download (436kB) | Preview |
Abstract
POEMS syndrome is a rareparaneoplastic disorder driven by an underlying low level plasma cell dyscrasiaand associated with elevated serum vascular endothelial growth factor (VEGF). Dueto its rarity, there are no internationally agreed standards of care, with verylimited data to guide management in the relapse setting. Agents used in myelomaare rational choices and have been employed. Daratumumab has been reported intwo case studies with lenalidomide-dexamethasone, one in the upfront and one inthe relapsed setting. We are the first to report here three cases ofdaratumumab-bortezomib-dexamethasone (DVd) use in relapsed POEMS postautologous stem cell transplant with good VEGF and clinical responses. Our casesadd to the literature on efficacy of daratumumab and are the first to report onits safe use with bortezomib in relapsed POEMS. It should be considered as aclinical option, in patients not responding to conventional first linetherapies.
| Type: | Article |
|---|---|
| Title: | Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/jha2.492 |
| Publisher version: | https://doi.org/10.1002/jha2.492 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Immunotherapy, multiple myeloma, myeloma, myeloma therapy |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10156161 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
